Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06179511 · ClinicalTrials.gov registry record · Phase 1

Study of AZD9829 in CD123+ Hematological Malignancies

A Phase 1 study of Hematological Malignancies, sponsored by AstraZeneca.

Active
Registry status
Phase 1
Development phase
56
Enrollment target
20
Study locations

NCT06179511 is a Phase 1 study of Hematological Malignancies that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 56 participants, below the 773-participant average among 16 other Hematological Malignancies trials with a reported enrollment target (93% lower). The trial reports 20 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06179511, a Phase 1 study of Hematological Malignancies, is active but no longer recruiting, sponsored by AstraZeneca.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
56 participants
Enrollment target
20
Study locations

Study Summary

This is a modular, multicentre, open-label, Phase I/II, dose-setting study. AZD9829 will be administered intravenously as monotherapy or in combination in participants with CD123 positive hematological malignancies.

Conditions Studied

Hematological Malignancies

Interventions

  • DRUG AZD9829

Study Locations (20)

Other

  • Research Site - Heidelberg
  • Research Site - Melbourne
  • Research Site - Tianjin
  • Research Site - Frankfurt
  • Research Site - Bologna
  • Research Site - Kashiwa
  • Research Site - Osaka
  • Research Site - Yoshida-gun
  • Research Site - Seoul
  • Research Site - Seoul
  • Research Site - Barcelona
  • Research Site - Salamanca
  • Research Site - Tainan

California

  • Research Site - Duarte

Missouri

  • Research Site - St Louis

New York

  • Research Site - New York

North Carolina

  • Research Site - Chapel Hill

Ohio

  • Research Site - Columbus

Texas

  • Research Site - Houston

Wisconsin

  • Research Site - Milwaukee

Trial Details

FieldValue
Enrollment Target 56 participants
Start Date 2024-01-31
Est. Completion 2026-03-23
Phase Phase 1

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06179511

The ClinicalTrials.gov registry entry for NCT06179511 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 773-participant average among 16 other Hematological Malignancies trials with a reported enrollment target (93% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Hematological Malignancies appearing as the primary indexed condition, and to 1 intervention - of which AZD9829 is the first listed.

NCT06179511 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Other, California, Missouri.

Frequently Asked Questions

What is clinical trial NCT06179511 about?

NCT06179511 is a clinical study titled "Study of AZD9829 in CD123+ Hematological Malignancies". This is a modular, multicentre, open-label, Phase I/II, dose-setting study. AZD9829 will be administered intravenously as monotherapy or in combination in participants with CD123 positive hematological malignancies.

What is the current status of trial NCT06179511?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2024-01-31. Estimated completion is 2026-03-23.

What conditions does trial NCT06179511 study?

This clinical trial studies the following conditions: Hematological Malignancies.

What interventions are being tested in trial NCT06179511?

The interventions under investigation include: AZD9829 (DRUG).

Who is sponsoring clinical trial NCT06179511?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06179511 being conducted?

This trial has 20 study locations across California, Missouri, New York, North Carolina, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hematological Malignancies

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Hematological Malignancies

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.